Company Overview
CardioDynamics (NASDAQ: CDIC) is committed to fundamentally changing drug management with ICG. The Company's primary product, the BioZ®, uses proprietary Impedance Cardiography (ICG) technology to noninvasively assess a patient's hemodynamics, data which typically has been unavailable in the physician's office and available on a limited basis in the hospital only through a time-consuming, costly, and potentially dangerous invasive procedure called Pulmonary Artery Catheterization (PAC), or the Swan Ganz Catheter.
Since the BioZ's ICG monitoring is noninvasive, it can be performed in outpatient areas such as physician offices, which have never before had access to hemodynamic information in treating heart failure, high blood pressure, pacemaker, and dialysis patients.
In physician offices, BioZ monitoring can decrease long term costs of hypertension management through the use of appropriate drug therapies. The reduction of blood pressure results in a decrease of more costly cardiovascular conditions including heart failure, strokes, and heart attacks.
In hospitals, BioZ monitoring on surgical or intensive care patients can decrease costs through the elimination of procedure risk, reduction of hospital stay, and minimization of hospital expenditures and personnel. BioZ monitoring can also provide valuable hemodynamic information in hospital areas where previously it has not been available, such as emergency departments, critical care, step-down units, and dialysis.
In this new era of cost containment, healthcare payors and providers are demanding greater efficiency and cost-effectiveness without diminishing the quality of care. The BioZ's ICG monitoring systems provide a solution to meet this growing demand.